The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Li, president, Merck Research Laboratories, until his retirement. Dr. Baynes will be succeeded by Dr. Eliav Barr, effective April 1, 2022.

Clinical Development 52

Clinical Development Vaccine Research Laboratories Laboratories 52

The Pharma Data

SEPTEMBER 28, 2021

10) and who haven’t received prior chemotherapy for metastatic disease. Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Source link: [link].

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. Lilly’s chief scientific officer and president of Lilly Research Laboratories. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

JUNE 2, 2023

Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. prostate cancer is the second most common cancer in men, and despite an increase in the number of available therapies for patients with mCRPC, five-year survival remains low. 0.45]) and overall survival (OS) (HR=0.30 [95% CI, 0.15-0.59])

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

AUGUST 31, 2021

today announced a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S. Food and Drug Administration (FDA) has converted this indication from an accelerated to a full (regular) approval. Source link: [link].

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

MARCH 17, 2021

KEYTRUDA reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.48-0.88]; We are driven to advance therapies to help improve outcomes for patients with blood cancers, including those with relapsed or refractory classical Hodgkin lymphoma, through our broad clinical program.”. months versus 8.3 months (95% CI, 10.9-19.4)

Therapies 52

Therapies Treatment Disease Trials 52

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

OCTOBER 12, 2021

The winning research receives 5,000 USD and a bronze horse for the research that has the highest translational potential; the investigator is awarded with 1,000 USD and the research laboratory 4,000 USD to continue the great work. We develop solutions and provide services to protect animals from disease and pain.

Research Laboratories 52

Research Laboratories Laboratories Therapies Production 52

The Pharma Data

JUNE 7, 2023

Patients who experience metastases at distant sites typically have worse survival outcomes and a poor prognosis, thus these results showing a reduction in the risk of distant recurrence underscore the potential of neoantigen therapy,” said Kyle Holen, M.D., Moderna’s Senior Vice President and Head of Development, Therapeutics and Oncology.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

PPD

OCTOBER 12, 2023

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.

Laboratories 52

Laboratories Protein Expression Clinical Trials Pharmacokinetics 52

The Pharma Data

JUNE 29, 2021

KEYTRUDA is First Anti-PD-1 Therapy Approved in Europe in Combination With Chemotherapy for First-Line Treatment of Advanced Esophageal or GEJ Cancer, Regardless of Histology. 0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; KENILWORTH, N.J.–(BUSINESS

Therapies 52

Therapies Treatment Disease Clinical Research 52

The Pharma Data

JUNE 1, 2022

Under her leadership, Pfizer advanced into clinical development or approval bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Group B Streptococcus, Neisseria meningitidis, Staphylococcus aureus, and Clostridium difficile. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

MARCH 16, 2021

This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

NOVEMBER 22, 2020

The drug is a once-daily oral precision therapy designed for highly potent and selective targeting of oncogenic RET alterations. PAH is a chronic, progressive disease caused by the hardening and narrowing of the pulmonary arteries that can cause right heart failure and eventual death. It was granted Priority Review. Source link.

FDA 52

FDA Licensing Licensing Treatment 52

The Pharma Data

JULY 22, 2021

Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation.

Therapies 52

Therapies Treatment Disease Trials 52

The Pharma Data

JULY 21, 2021

mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. In the EU, VERQUVO (2.5 VERQUVO is being jointly developed by Merck and Bayer AG. mg, 5 mg and 10 mg).

Treatment 52

Treatment Production Disease FDA Approval 52

The Pharma Data

JUNE 7, 2022

Based on a post hoc analysis, fewer LAGEVRIO-treated participants in the MITT population required respiratory interventions (including conventional oxygen therapy, a high-flow heated and humidified device, noninvasive mechanical ventilation, or invasive mechanical ventilation) versus placebo-treated participants, with a RRR of 34.3% [95% CI, 4.3%

Hospitals 40

Hospitals Research Laboratories Treatment Disease 40

The Pharma Data

SEPTEMBER 7, 2021

In China, esophageal and gastroesophageal junction cancers are leading causes of death, and there have been few treatment advances for patients over the past several decades,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. The median OS was 12.4 months (95% CI, 10.5-14.0)

Treatment 52

Treatment Research Laboratories Packaging Laboratories 52

The Pharma Data

APRIL 28, 2023

Results from the PROpel trial showed a statistically significant and clinically meaningful 34% reduction in the risk of radiographic disease progression or death with LYNPARZA plus abi/pred (HR=0.66 [95% CI, 0.54-0.81]; indication, patients are selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. In the U.S.,

FDA 40

FDA FDA Approval Trials Treatment 40

The Pharma Data

OCTOBER 19, 2020

Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

APRIL 11, 2021

50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity. Initiate or adjust anti-hypertensive therapy as appropriate. Retevmo has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction. Retevmo is an U.S.

Research 52

Research Therapies Treatment Trials 52

The Pharma Data

JANUARY 20, 2021

“The approval of Verquvo provides doctors, health care professionals, and patients with a welcome new option to current available therapies.”. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Therapy was initiated at Verquvo 2.5 Kenilworth, N.J.,

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies.

Small Molecule 52

Small Molecule Engineering Clinical Development Pharmaceuticals 52

The Pharma Data

OCTOBER 23, 2021

10) and Who Have Not Received Prior Chemotherapy for Metastatic Disease. KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From the Phase 3 KEYNOTE-355 Study.

Treatment 52

Treatment Research Laboratories Trials Laboratories 52

The Pharma Data

APRIL 16, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

MARCH 15, 2022

The safety profile of KEYTRUDA in combination with LYNPARZA in this trial was consistent with that observed in previously reported studies for the individual therapies; however, the combination was associated with a higher incidence of grade 3-5 adverse events and drug-related serious adverse events, compared to the control arm.

DNA 52

DNA Clinical Trials Trials Therapies 52

Conversations in Drug Development Trends

DECEMBER 12, 2022

Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. What is the difference between a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory vs a research laboratory?

Clinical Trials 52

Clinical Trials Trials Laboratories Research Laboratories 52

The Pharma Data

JULY 15, 2021

The trial investigated neoadjuvant KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy followed by adjuvant KEYTRUDA as monotherapy (the KEYTRUDA regimen) compared with neoadjuvant chemotherapy followed by adjuvant placebo (the chemotherapy-placebo regimen) in patients with high-risk early-stage triple-negative breast cancer (TNBC).

Therapies 52

Therapies Treatment Trials FDA 52

Codon

JULY 21, 2024

Of course, AA and P-line rats are not the only research animals bred for the study of disease. The most famous of these is the Oncomouse , engineered in 1984 for the express purpose of developing tumors so that researchers could study cancer in living organisms, rather than in petri dishes. 1 Subscribe to Asimov Press.

Research 112

Research Engineering Disease Science 112

The Pharma Data

JULY 21, 2021

In the ongoing Phase 2a (NCT04003103) randomized, double-blind, parallel assignment, placebo-controlled, multicenter trial in adults at low-risk for acquiring HIV-1 infection, participants were randomly assigned (2:2:1) to one of three oral once-monthly therapy groups: islatravir 60 mg, islatravir 120 mg or placebo. Kenilworth, N.J.,

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

Codon

APRIL 2, 2023

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. Read A one-time gene therapy injection for spinal muscular atrophy. Gene Therapy. Nature Neuroscience. Read You love to see it! Trends in Biotechnology. ” Max Bayer.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

NOVEMBER 18, 2021

50 copies/mL, demonstrating that antiviral efficacy was comparable between DOR/ISL and different antiretroviral therapy regimens (ILLUMINATE SWITCH A) and between DOR/ISL and bictegravir/emtricitabine/tenofovir (ILLUMINATE SWITCH B). About IMAGINE-DR. Source link: [link].

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

MARCH 5, 2021

Currently available BTK inhibitors irreversibly inhibit BTK and the long-term efficacy of these therapies can be limited by acquired resistance, most commonly through BTK C481 mutations. In rapidly growing tumors with inherently high rates of BTK turnover, resistance to covalent BTK therapies may be the result of incomplete target inhibition.

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials Therapies 52

The Pharma Data

APRIL 7, 2023

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.

Trials 40

Trials Clinical Trials Treatment Therapies 40

The Pharma Data

AUGUST 30, 2021

today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA). It is an aggressive type of breast cancer that has a high risk for disease recurrence. months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5), 0.80; p=0.0002) and doubled median PFS (16.5

Treatment 52

Treatment Trials Research Laboratories Clinical Trials 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. After a median follow-up of 13.4 months).

FDA Approval 52

FDA Approval FDA Treatment Therapies 52